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ABSTRACT
Introduction The Transparent Reporting of a multivariable 
prediction model of Individual Prognosis Or Diagnosis 
(TRIPOD) statement and the Prediction model Risk Of 
Bias ASsessment Tool (PROBAST) were both published to 
improve the reporting and critical appraisal of prediction 
model studies for diagnosis and prognosis. This paper 
describes the processes and methods that will be used to 
develop an extension to the TRIPOD statement (TRIPOD- 
artificial intelligence, AI) and the PROBAST (PROBAST- AI) 
tool for prediction model studies that applied machine 
learning techniques.
Methods and analysis TRIPOD- AI and PROBAST- AI 
will be developed following published guidance from 
the EQUATOR Network, and will comprise five stages. 
Stage 1 will comprise two systematic reviews (across all 
medical fields and specifically in oncology) to examine 
the quality of reporting in published machine- learning- 
based prediction model studies. In stage 2, we will 
consult a diverse group of key stakeholders using a 
Delphi process to identify items to be considered for 
inclusion in TRIPOD- AI and PROBAST- AI. Stage 3 will be 
virtual consensus meetings to consolidate and prioritise 
key items to be included in TRIPOD- AI and PROBAST- AI. 
Stage 4 will involve developing the TRIPOD- AI checklist 
and the PROBAST- AI tool, and writing the accompanying 
explanation and elaboration papers. In the final stage, 
stage 5, we will disseminate TRIPOD- AI and PROBAST- 
AI via journals, conferences, blogs, websites (including 
TRIPOD, PROBAST and EQUATOR Network) and social 
media. TRIPOD- AI will provide researchers working on 
prediction model studies based on machine learning 
with a reporting guideline that can help them report key 
details that readers need to evaluate the study quality and 
interpret its findings, potentially reducing research waste. 
We anticipate PROBAST- AI will help researchers, clinicians, 
systematic reviewers and policymakers critically appraise 
the design, conduct and analysis of machine learning 
based prediction model studies, with a robust standardised 
tool for bias evaluation.
Ethics and dissemination Ethical approval has been 
granted by the Central University Research Ethics 
Committee, University of Oxford on 10- December-2020 
(R73034/RE001). Findings from this study will be 
disseminated through peer- review publications.
PROSPERO registration number CRD42019140361 and 
CRD42019161764.
BACKGROUND
Models that predict clinical outcomes are 
abundant in the medical literature and are 
broadly categorised as those that estimate 
the probability of the presence of a particular 
outcome (diagnostic) or whether a particular 
outcome (eg, event) will occur in the future 
(prognostic).1 Traditionally, these models 
(herein referred to as prediction models) 
have been developed using regression- based 
methods, typically logistic regression for 
short- term outcomes and Cox regression for 
longer- term outcomes.2 Numerous reviews 
have observed that studies describing the 
Strengths and limitations of this study
 ► The reporting of clinical prediction models using ar-
tificial intelligence is poor.
 ► There are no guidelines for the reporting or risk of 
bias assessment of clinical prediction models using 
artificial intelligence.
 ► The strengths of this study is that it follows pub-
lished guidance from the EQUATOR Network for de-
veloping reporting guidelines.
 ► Expert opinion and consensus will be obtained from 
multiple stakeholders (statisticians, clinician scien-
tists, epidemiologists, computer scientists, funders, 
healthcare policy- makers, patients and industry 
leaders).
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development and validation (including updating) of a 
prediction model often fail to report key information to 
help readers judge the methods and have a complete, 
transparent and clear picture of the model’s predictive 
accuracy and other relevant details such as the target 
population and the content of the model itself.3–6 The 
absence of full and comprehensive reporting limits the 
usability of the findings of these studies, for example, in 
subsequent validation studies, evidence synthesis studies 
or in daily practice, and therefore, contribute to research 
waste.7 In response to this, in 2015, the Transparent 
Reporting of a multivariable prediction model for Indi-
vidual Prognosis Or Diagnosis (TRIPOD) Statement was 
published.1 8 The TRIPOD Statement is a checklist of 22 
items that authors should report with sufficient detail and 
clarity to inform how the study was carried out.
Since the publication of the TRIPOD Statement, artifi-
cial intelligence (AI) and in particular machine learning, 
approaches to clinical prediction have evolved and grown 
in popularity with the number of AI and machine learning 
publications rapidly rising.9–14 This is evident within a 
recent review of COVID-19 related prediction models, 
where 57 (out of 107 included studies) used machine 
learning methods to develop their model.15
Machine learning, a branch of AI, can be broadly 
described as data analytical methods that learn from data 
without being explicitly programmed, with patterns iden-
tified based on the data itself. They are often described as 
having flexibility to capture complex associations partic-
ularly in large and unstructured data and complexity in 
modelling. While the vast majority of the items in the 
TRIPOD Statement are relevant to machine learning 
based prediction model studies, there are some unique 
challenges with machine learning that are not captured. 
Due to their complexity, these prediction models are typi-
cally considered to be ‘black box’, unlike say regression- 
based models where the full model can be transparently 
presented (eg, as an equation containing all the regres-
sion coefficients). Also, while many machine learning 
methods have origins in the statistical literature, two 
(overlapping) prediction model cultures have emerged 
as those from a statistical/epidemiological background 
and those from the computer science/data sciences.16 
Although there is clear overlap, different approaches 
to model development, validation and updating have 
appeared, and different and sometimes conflicting termi-
nology have arisen.
Due to the relative novelty of applying machine- 
learning methods to clinical prediction modelling, there 
is little information on the quality of reporting of these 
studies. However, the few reviews that have examined 
the completeness of reporting of have concluded that 
reporting is poor.17 18 In response to these concerns, 
guidance is required to help authors fully describe their 
prediction model study when machine learning methods 
were used. Therefore the TRIPOD group initiated a 
large international project to develop a consensus based 
extension of TRIPOD with specific focus on reporting 
of studies that undertake the development, validation 
or updating of a diagnostic or prognostic prediction 
model, using machine learning techniques—herein 
referred to as TRIPOD- AI.19 The TRIPOD- AI extension, 
comprising a checklist and an accompanying elabora-
tion and explanation document will provide researchers, 
authors, reviewers, editors, users and other stakeholders 
of machine- learning- based prediction model studies, 
with guidance on the minimal set of items to report, with 
detailed examples of good reporting for each item.
Complete reporting allows studies to be understood, 
replicated and used. However, critical appraisal and of 
the quality of study method is a crucial component of 
evidence- based medicine as well. Critical appraisal and 
assessing the quality of studies is a crucial component 
of evidence- based medicine. In 2019, the Prediction 
model Risk Of Bias ASsessment Tool (PROBAST) was 
published20 21 to help a variety of stakeholders including, 
for example, systematic reviewers, researchers, journal 
editors, manuscript reviewers and policy- makers involved 
in clinical guideline development, critically appraise the 
study design, conduct and analysis of prediction model 
studies. PROBAST comprises four domains (participants, 
predictors, outcome and analysis) and contains 20 signal-
ling questions to facilitate risk of bias assessment. Clearly 
risk of bias assessment and reporting are intrinsically 
linked, in that judging risk of bias is predicated on what 
has been reported in the primary study. While in principle 
PROBAST is relevant for prediction model studies using 
machine learning, different approaches to model devel-
opment and validation, and terminology have appeared, 
and the ability to critically appraise these studies is crucial 
before they are implemented.22 23 Therefore, in parallel 
with the development of TRIPOD- AI, we will also develop 
PROBAST- AI, a tool to assess risk of bias in machine 
learning based multivariable prediction model studies.
FOCUS OF TRIPOD-AI AND PROBAST-AI
The focus of both TRIPOD- AI and PROBAST- AI is on 
reports of research or endeavours in which a multivari-
able prediction model is being developed (or updated), 
or validated (tested) using any (supervised) machine 
learning technique. Conforming to the original TRIPOD 
and PROBAST publications, a multivariable prediction 
model is defined as any combination or equation of two 
or more predictors that is to be used for individualised 
predictions to estimate an individual’s probability of 
having (diagnosis) or developing (prognosis) a partic-
ular health outcome or state. Predictors may have any 
form and emerge from patient history, physical exam-
ination, diagnostic, prognostic or monitoring tests and 
from undergone treatments. Outcomes may also have 
any form (dichotomous, categorical, continuous) and 
of any kind, such as, a particular condition or disorder 
being present or absent (diagnostic outcome or classi-
fication), short- term prognosis outcomes (eg, hospital 
mortality or postoperative complications), and long- term 
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prognostic outcomes such as 1- year occurrence of treat-
ment complications, 5- year occurrence of metastases or 
lifelong survival).
As per the original publications, TRIPOD- AI and 
PROBAST- AI will also address prediction model studies 
from all medical care settings (public health, primary, 
secondary, tertiary and nursing home care) and all 
corresponding target populations (healthy individuals, 
suspected and diseased individuals).
TRIPOD- AI and PROBAST- AI are not meant to address:
 ► Comparative studies that quantify the impact of using 
a prediction model as compared with not using the 
model.24
 ► So- called predictor finding studies (also known as 
risk or prognostic factor studies) where multivari-
able machine learning techniques are used to iden-
tify (usually from a wider set of potential predictors) 
those predictors that are associated with an outcome, 
but not to develop a model that can be used for indi-
vidualised predictions in new individuals.
 ► Single medical test studies that use machine learning 
or AI techniques aimed to read, for example, CT or 
MRI, images to find which image parameters are best 
associated with an outcome (such studies fall under 
the remit of STARD- AI25). If these image parameters 
are included as predictors in a multivariable model 
combined with other predictors, TRIPOD- AI and 
PROBAST- AI may be useful.
METHODS/DESIGN
Both TRIPOD- AI and PROBAST- AI will be developed 
following published guidance from the EQUATOR 
Network.26 We will develop the guideline in five stages: 
(1) systematic reviews to establish the quality of current 
reporting, (2) Delphi exercise, (3) consensus meeting, (4) 
development of the guidance statement and (5) guideline 
dissemination. We have registered our intent to develop 
the TRIPOD extension for AI on the EQUATOR Network 
website ( www. equator- network. org), the TRIPOD website 
( www. tripod- statement. org) and recently announced it 
in the Lancet,19 while the PROBAST- AI development has 
been announced on the PROBAST website ( www. probast. 
org).
TRIPOD-AI/PROBAST-AI working group
The TRIPOD/PROBAST working group will include: 
(1) an executive committee (2) an advisory and working 
group and (3) a large international Delphi panel.
The TRIPOD- AI/PROBAST- AI executive committee 
will be responsible for the leadership and coordination 
of all the processes involved in the development and 
dissemination of the TRIPOD- AI guideline. The exec-
utive committee consists of the two lead authors of the 
TRIPOD reporting guideline and the PROBAST tool, 
and also prediction model experts and researchers from 
the machine learning community. Key stakeholders for 
stage 2 (Delphi survey) will be identified and approached 
to participate and a subset of these key stakeholders (the 
advisory group) will participate in stage 3 (consensus 
meeting).
Here, the term key stakeholder refers to a cross- sector 
participant (both industry and public sector) who falls 
into at least one of the following categories:
1. Researchers who have used machine learning in the 
context of clinical prediction, have clear knowledge 
and expertise in using machine learning or developed 
machine learning methods. These include applied 
(bio)medical investigators, statisticians, epidemiolo-
gists and data scientists).
2. Assessors and approvers of AI or machine learning 
model, such as regulatory assessors and ethics commit-
tee members.
3. Beneficiaries or users of the resultant TRIPOD- AI 
guidance and PROBAST- AI tool such as journal editors 
and journal reviewers.
4. Commissioners of research grants, such as funders.
5. Consumers of research results such as healthcare pro-
viders and patients and citizens.
Stage 1: systematic review of current reporting
Two parallel systematic reviews are ongoing to evaluate 
the quality of current reporting in published studies devel-
oping, validating or updating machine learning based 
prediction models in the medical domain. Both system-
atic reviews will assess adherence of the reporting against 
the original TRIPOD Statement,1 8 using the TRIPOD 
adherence checklist.27 The reviews will also examine the 
methodological conduct of the primary studies, including 
a risk of bias assessment using the recently issued risk of 
bias tool (quality appraisal) for diagnostic and prognostic 
prediction model studies (PROBAST),20 21 and will draw 
out specific issues, currently not covered by TRIPOD 
and PROBAST relating to machine learning. The proto-
cols for the two systematic reviews have been registered 
with the International Prospective Register of System-
atic Reviews (PROSPERO IDs CRD42019140361 and 
CRD42019161764). One review (CRD42019161764) will 
examine the quality of reporting of machine- learning- 
based prediction model studies across all medical fields 
(between January 2018 to December 2019), while the 
other review (CRD42019140361) will focus on the quality 
of reporting of machine learning based prediction model 
studies published in oncology (between January 2019 and 
September 2019).
Undertaking these reviews serves two purposes: (1) 
to understand the completeness of current reporting of 
machine- learning- based prediction model studies in the 
medical literature and (2) to identify unique reporting 
items for consideration for TRIPOD extension, and 
unique risk of bias or quality items for PROBAST exten-
sion. The data collection for this phase is underway. 
The reviews will evaluate the current completeness of 
reporting and the quality of the research and identify 
additional reporting and quality items to be considered 
for TRIPOD- AI and PROBAST- AI.
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These two reviews will evaluate the current complete-
ness of reporting and the quality of the research. Together 
with other evidence3 4 17 18 28 from existing methodological 
guidance papers, they will provide important information 
on the transparency and quality of reporting. Using the 
original TRIPOD and PROBAST checklists as starting 
points, the executive committee will identify in the liter-
ature the preliminary items to consider in stage 2 (the 
Delphi study) and therefore inclusion in the eventual 
TRIPOD- AI checklist and PROBAST- AI tool.
Stage 2: Delphi exercise
We will perform an extensive Delphi survey among a 
large international network of relevant stakeholders, with 
a maximum of three rounds, to help decide on items 
that could be modified, added to, or removed from the 
TRIPOD 2015 checklist to form the TRIPOD- AI checklist, 
and subsequently the PROBAST- AI checklist.
Design
The Delphi process will comprise of a series of rounds 
where panellists will independently and anonymously 
evaluate and achieve consensus on the inclusion or exclu-
sion of the proposed reporting and quality items—in 
addition to suggesting additional items. The process will 
be repeated for a maximum of three rounds. Following 
each round, participants will be provided with struc-
tured feedback of the previous round to help reconcile 
individual opinions and achieve group consensus. Items 
achieving a high level of agreement (≥70%) will be taken 
forward to the consensus meeting (stage 3).
Selection of potential items
The list of items for TRIPOD- AI (and PROBAST- AI) will 
be collated by the executive committee, including the 
results of the two systematic reviews, any other available 
studies on methodology or reporting of machine learning 
based prediction models, and expert recommendations 
from the Delphi panellists. Relevant methodological 
guidance or methodological papers will be retrieved to 
identify additional candidate reporting and quality items 
for machine- learning- based prediction model studies. 
Preselection involves dividing items into those to further 
consider, those that can be provided as optional guid-
ance (to be outlined in an Explanation and Elaboration 
accompanying document), or those not to consider for 
potential inclusion. Delphi participants will have the 
opportunity to view and provide feedback in each round, 
and also to suggest new items.
Recruitment process and participants
Delphi participants will be identified through profes-
sional networks of the executive committee, participation 
in the Delphi exercise of the original TRIPOD guideline 
(and TRIPOD for Abstracts and TRIPOD Cluster Delphi 
surveys), original PROBAST Delphi exercise, via self- 
response to the Lancet 2019 paper where TRIPOD- AI was 
announced,19 and responses to social media announce-
ments of TRIPOD- AI (eg, Twitter).
We will invite international participants with diverse 
roles (eg, researchers, healthcare professionals, journal 
editors, funders, policy makers, healthcare regulators, 
end users of prediction models) from a range of settings 
(eg, universities, hospitals, primary care, biomedical 
journals, non- profit organisations and for- profit organ-
isations). Participants will be invited via personalised 
email that will describe the TRIPOD- AI extension and 
PROBAST- AI tool development, and explain the objec-
tive, process, and timelines of the Delphi exercise. We 
plan to invite at least 200 participants to the Delphi survey. 
In all rounds, the survey will remain open for 3 weeks, 
with a reminder email sent 1 week after the initial invi-
tation. In round two of the Delphi exercise, additional 
participants may be sought to ensure fair representation 
of all key stakeholders.29
Informed consent from participants will be obtained 
using an online consent form and participants can with-
draw at any time. Individuals who indicate that they wish 
to opt out of the survey will be removed from subsequent 
invitations. Participants will not know the identities of 
other individuals in the Delphi panel, nor will they know 
the specific answers that any individual provides.
Procedure for selection of items
We plan to ask participants to consider the following 
guiding principles when reviewing existing, new or modi-
fied items for inclusion: (1) reporting of the item should 
facilitate reproducibility of the study (ie, users should be 
able to recreate the findings based on the information 
reported); (2) reporting of the item facilitates assess-
ment of the quality and risk of bias in and applicability 
of the machine learning study findings, to enhance their 
uptake and use in subsequent studies, systematic reviews 
and daily practice; (3) item is likely relevant to nearly all 
prediction model studies; (4) the set of items represent 
the minimum that should be reported in all machine 
learning studies developing, validating or updating a 
diagnostic or prognostic prediction model.
Round 1
Participants will be asked to rate on a 5- point Likert 
scale, the extent to which they agree with the inclusion 
of each checklist item in the TRIPOD- AI extension and 
PROBAST- AI tool (1=strongly disagree, 2=somewhat 
disagree, 3=I don’t know, 4=somewhat agree, 5=strongly 
agree). A free- text box will be provided for general 
comments on each item (to justify their decision or 
suggest wording changes), and a free- text box will be 
provided at the end of the survey to suggest additional 
checklist items or provide general comments on the 
checklist. The survey will be pilot- tested for usability 
and clarity to a small number of individuals familiar 
with prediction models or machine learning but not 
involved in the TRIPOD- AI guideline extension or 
PROBAST- AI tool and revised accordingly based on 
their feedback.
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Round 2
The same participants involved in round 1 will be invited 
to participate in round 2. Participants will be provided 
with their first- round responses on each item, an anony-
mised summary of the group ratings and anonymised 
comments to justify ratings. Using the same format as 
round 1, participants will be presented with each item, 
including any new items suggested during round 1, and 
again express the extent to which they agree with the 
inclusion of the item in the TRIPOD- AI checklist or 
PROBAST- AI tool, considering the structured feedback 
to inform their responses. Participants who were invited 
to participate in round 1, but who did not respond will be 
invited to participate in round 2, and will be presented 
with an anonymised summary of the group ratings. Items 
that reached a high- level of agreement (scoring 4 or 5) 
in round 1 (≥70%) will be presented for information 
purposes only, with no voting on these items, though a 
free- text box will be provided for any comments. A third 
Delphi round will be used if deemed necessary by the 
Executive Committee.
Results from the Delphi survey
Item scores will be summarised for the entire panel as 
a whole, as appropriate (eg, frequency and proportions 
across the rating categories) accompanied by a narra-
tive summary of findings, comments, and suggestions. 
Results from both rounds of the survey will be discussed 
by the executive committee. For items where there was 
no consensus following the second Delphi found will be 
discussed by the executive committee, and will be consid-
ered for discussion at the subsequent consensus meeting.
Stage 3: consensus meeting
Two virtual consensus meetings (separately for TRIPOD- AI 
and PROBAST- AI), both spread over 2 days, will be held 
with the objective of discussing the results from the 
Delphi exercise and finalising items to be included in the 
reporting guideline and risk of bias tool. The composi-
tion of the consensus group will reflect the diversity of 
the key stakeholders addressed above. Key experts partici-
pating in the Delphi exercise will be considered to partic-
ipate in the consensus meeting. We will also consider 
inviting experts who did not contribute to the Delphi 
to participate in the consensus. A total of around 25–30 
international participants are expected to contribute to 
the virtual consensus meeting.
Procedure
The agenda and any material (eg, results from the system-
atic reviews and Delphi) for the consensus meeting will be 
prepared by the executive committee and will be shared 
with attendees in advance. Members of the executive 
committee will facilitate a structured discussion on the 
rationale behind each item identified in the Delphi exer-
cise. Consensus meeting participants will then be given 
the opportunity to discuss each item (reporting item for 
TRIPOD- AI and signalling question for PROBAST- AI), 
and vote on each item. The decision to retain an item 
in the TRIPOD- AI and PROBAST- AI will be based on 
achieving at least 70% support from the consensus 
meeting participants. The group will agree on the draft 
list of reporting items for the final TRIPOD- AI extension 
and PROBAST- AI tool. Specific item wording will not be 
discussed during the meeting, though participants can 
suggest and the group to agree on general intent and 
meaning of the item. Plans for dissemination will be 
discussed at the end of the consensus meeting.
Pilot testing
We will invite authors of machine learning prediction 
model studies in the medical domain, doctoral students 
undertaking prediction model, machine learning courses 
or workshops, and peer- reviewers and editors of journals 
who frequently publish such prediction model studies, to 
pilot the use of a draft version of the TRIPOD- AI checklist 
and PROBAST- AI tool. We will ask those who pilot the 
checklist and tool whether the wording of items is ambig-
uous or difficult to interpret.
Stage 4: development of the draft TRIPOD-AI statement, 
PROBAST-AI and explanation and elaboration documents
The executive committee will lead the development of the 
TRIPOD- AI reporting guidance and PROBAST- AI signal-
ling questions based on the agreed list of items from the 
consensus meeting (stage 3). The executive committee 
will invite a subset of members from the consensus 
meeting (to form a writing group) to help draft the expla-
nation and elaboration paper.
The executive committee will reserve the right to 
update (ie, remove or add) additional items to the 
TRIPOD- AI checklist during the development of the 
TRIPOD- AI statement, if and as necessary (as a result of 
the pilot testing).
For each of the TRIPOD- AI extension and the 
PROBAST- AI risk of bias tool, two manuscripts will be 
developed: (1) the statement paper, presenting the check-
list/tool and describing the process of how it was devel-
oped and (2) an explanation and elaboration paper. The 
explanation and elaboration papers will outline the ratio-
nale of the reporting items (TRIPOD- AI) and signalling 
questions (PROBAST- AI), examples of good reporting 
(TRIPOD- AI) and examples of how to use PROBAST- AI. 
Drafts of the papers will be circulated to all participants of 
the consensus meeting for their comments.
Stage 5: guideline dissemination
The dissemination strategy will be informed by discussions 
at the consensus meeting. We will aim to seek simultaneous 
publication in key journals to target different readerships. 
To increase visibility and aid uptake, the TRIPOD- AI 
checklist and PROBAST- AI tool will be published open 
access, and made available on the TRIPOD website along 
with other TRIPOD extensions ( www. tripod- statement. 
org), and on the PROBAST website ( www. probast. org) 
respectively, as well on the PROGRESS website ( www. 
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prognosisresearch. com). The TRIPOD- AI extension will 
be indexed on the EQUATOR website ( www. equator- 
network. org). Social media will be used to help dissem-
inate the extension. The Executive Committee will (and 
consensus participants will be encouraged to) publicise 
the TRIPOD- AI statement and PROBAST- AI tool at key 
conferences and courses.
PUBLICATION PLAN
It is envisaged that the following publications will arise 
from the TRIPOD- AI and PROBAST- AI initiative:
 ► Publication 1: study protocol.
 ► Publication 2: systematic review protocol (with regis-
tration on PROSPERO).
 ► Publication 3 and 4: Systematic reviews.
 ► Publication 5 & 6: TRIPOD- AI statement and the 
Explanation and Elaboration paper.
 ► Publication 7 & 8: PROBAST- AI tool and the Explana-
tion and Elaboration paper.
CONCLUSION
The number of prediction model studies using machine 
learning methods is rapidly increasing, including devel-
oped, validated or updated prediction models. Ensuring 
that key details are reported is important so that readers 
can evaluate the study quality, and interpret its findings 
including the developed, validated or updated prediction 
model to enhance their uptake in subsequent research 
(eg, validation studies), evidence synthesis projects (eg, 
systematic reviews of prediction models) and in daily 
practice by healthcare professionals, patients or citizens. 
We anticipate that TRIPOD- AI will help authors trans-
parently report their study and help reviewers, editors, 
policy- makers and end- users understand the methods and 
findings, and thereby reduce research waste. Similarly, we 
anticipate PROBAST- AI will help researchers, clinicians, 
systematic reviewers and policy- makers critically appraise 
the design, conduct and analysis of machine- learning- 
based prediction model studies.
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